PML degradation: Multiple ways to eliminate PML

Frontiers in Oncology

Volumn 3 MAR, Issue , 2013, Pages

  Rabellino, Andrea ^a   Scaglioni, Pier Paolo ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Degradation; PML; Sumoylation; Tumor suppressor; Ubiquitination

Indexed keywords

ARSENIC TRIOXIDE; BETA1 INTEGRIN; CASEIN KINASE II; CHECKPOINT KINASE 2; HYPOXIA INDUCIBLE FACTOR 1; INOSITOL 1, 4, 5 TRISPHOSPHATE RECEPTOR; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PEPTIDYLPROLYL ISOMERASE PIN1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P53; TELOMERASE; UNCLASSIFIED DRUG; VASCULOTROPIN; VIRUS PROTEIN;

ACETYLATION; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; DNA DAMAGE; DNA REPAIR; HEMATOPOIETIC STEM CELL; HUMAN; HYPOXIA; LEUKEMOGENESIS; LUNG NON SMALL CELL CANCER; NEOANGIOGENESIS; NONHUMAN; PHOSPHORYLATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; RETINOBLASTOMA; REVIEW; SENESCENCE; SUMOYLATION; UBIQUITINATION; VIRUS INFECTION; VIRUS REPLICATION;

EID: 84883290530     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00060     Document Type: Review

References (105)

1. Ablain, J., and de The, H. (2011). Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood 117, 5795-5802.
2. Adamson, A. L., and Kenney, S. (2001). Epstein-Barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J. Virol. 75, 2388-2399.
3. Ahn, J. H., Brignole, E. J. III, and Hayward, G. S. (1998). Disruption of PML subnuclear domains by the acidic IE1 protein of human cytomegalovirus is mediated through interaction with PML and may modulate a RING finger-dependent cryptic transactivator function of PML. Mol. Cell. Biol. 18, 4899-4913.
4. Bernardi, R., Guernah, I., Jin, D., Grisendi, S., Alimonti, A., Teruya-Feldstein, J., et al. (2006). PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 442, 779-785.
5. Bernardi, R., and Pandolfi, P. P. (2007). Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat. Rev. Mol. Cell Biol. 8, 1006-1016.
6. Bernardi, R., Papa, A., and Pandolfi, P. P. (2008). Regulation of apoptosis by PML and the PML-NBs. Oncogene 27, 6299-6312.
7. Bernardi, R., Scaglioni, P. P., Bergmann, S., Horn, H. F., Vousden, K. H., and Pandolfi, P. P. (2004). PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat. Cell Biol. 6, 665-672.
8. Bischof, O., Kirsh, O., Pearson, M., Itahana, K., Pelicci, P. G., and Dejean, A. (2002). Deconstructing PML-induced premature senescence. EMBO J. 21, 3358-3369.
9. Borden, K. K. (2002). Pondering the promyelocytic leukemia protein (PML) puzzle: Possible functions for PML nuclear bodies. Mol. Cell. Biol. 22, 5259-5269.
10. Campisi, J., and d'Adda di Fagagna, F. (2007). Cellular senescence: When bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 8, 729-740.
11. Chelbi-Alix, M. K., and de The, H. (1999). Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML, and Sp100 proteins. Oncogene 18, 935-941.
12. Chelbi-Alix, M. K., Pelicano, L., Quignon, F., Koken, M. H., Venturini, L., Stadler, M., et al. (1995). Induction of the PML protein by interferons in normal and APL cells. Leukemia 9, 2027-2033.
13. Chen, R. H., Lee, Y. R., and Yuan, W. W. (2012). The role of PML ubiquitination in human malignancies. J. Biomed. Sci. 19, 81.
14. Collado, M., and Serrano, M. (2006). The power and the promise of oncogene-induced senescence markers. Nat. Rev. Cancer 6, 472-476.
15. Collado, M., and Serrano, M. (2010). Senescence in tumours: Evidence from mice and humans. Nat. Rev. Cancer 10, 51-57.
16. Cozza, G., Pinna, L. A., and Moro, S. (2012). Kinase Ck2 inhibition. An update. Curr. Med. Chem. 20, 671-693.
17. Daniel, M. T., Koken, M., Romagne, O., Barbey, S., Bazarbachi, A., Stadler, M., et al. (1993). The PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 82, 1858-1867.
18. de Stanchina, E., Querido, E., Narita, M., Davuluri, R. V., Pandolfi, P. P., Ferbeyre, G., et al. (2004). PML is a direct p53 target that modulates p53 effector functions. Mol. Cell 13, 523-535.
19. de The, H., and Chen, Z. (2010). Acute promyelocytic leukaemia: Novel insights into the mechanisms of cure. Nat. Rev. Cancer 10, 775-783.
20. de The, H., Chomienne, C., Lanotte, M., Degos, L., and Dejean, A. (1990). The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 347, 558-561.
21. de The, H., Le Bras, M., and Lallemand-Breitenbach, V. (2012). The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies. J. Cell Biol. 198, 11-21.
22. Dellaire, G., and Bazett-Jones, D. P. (2004). PML nuclear bodies: Dynamic sensors of DNA damage and cellular stress. Bioessays 26, 963-977.
23. Dyck, J. A., Maul, G. G., Miller, W. H. Jr., Chen, J. D., Kakizuka, A., and Evans, R. R. (1994). A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 76, 333-343.
24. Everett, R. D., and Maul, G. G. (1994). HSV-1 IE protein Vmw110 causes redistribution of PML. EMBO J. 13, 5062-5069.
25. Everett, R. R. (2001). DNA viruses and viral proteins that interact with PML nuclear bodies. Oncogene 20, 7266-7273.
26. Fagioli, M., Alcalay, M., Pandolfi, P. P., Venturini, L., Mencarelli, A., Simeone, A., et al. (1992). Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms. Oncogene 7, 1083-1091.
27. Fanelli, M., Fantozzi, A., De Luca, P., Caprodossi, S., Matsuzawa, S., Lazar, M. A., et al. (2004). The coiled-coil domain is the structural determinant for mammalian homologues of Drosophila Sina-mediated degradation of promyelocytic leukemia protein and other tripartite motif proteins by the proteasome. J. Biol. Chem. 279, 5374-5379.
28. Ferbeyre, G., de Stanchina, E., Querido, E., Baptiste, N., Prives, C., and Lowe, S. S. (2000). PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 14, 2015-2027.
29. Ferguson, A. D., Sheth, P. R., Basso, A. D., Paliwal, S., Gray, K., Fischmann, T. O., et al. (2011). Structural basis of CX-4945 binding to human protein kinase CK2. FEBS Lett. 585, 104-110.
30. Fu, C., Ahmed, K., Ding, H., Ding, X., Lan, J., Yang, Z., et al. (2005). Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3. Oncogene 24, 5401-5413.
31. Galanty, Y., Belotserkovskaya, R., Coates, J., Polo, S., Miller, K. M., and Jackson, S. S. (2009). Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature 462, 935-939.
32. Galat, A. (2003). Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity-targets-functions. Curr. Top. Med. Chem. 3, 1315-1347.
33. Gambacorta, M., Flenghi, L., Fagioli, M., Pileri, S., Leoncini, L., Bigerna, B., et al. (1996). Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues. Am. J. Pathol. 149, 2023-2035.
34. Geoffroy, M. C., and Chelbi-Alix, M. K. (2011). Role of promyelocytic leukemia protein in host antiviral defense. J. Interferon Cytokine Res. 31, 145-158.
35. Giorgi, C., Ito, K., Lin, H. K., Santangelo, C., Wieckowski, M. R., Lebiedzinska, M., et al. (2010). PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science 330, 1247-1251.
36. Goddard, A. D., Borrow, J., Freemont, P. S., and Solomon, E. (1991). Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 254, 1371-1374.
37. Guo, A., Salomoni, P., Luo, J., Shih, A., Zhong, S., Gu, W., et al. (2000). The function of PML in p53-dependent apoptosis. Nat. Cell Biol. 2, 730-736.
38. Gurrieri, C., Capodieci, P., Bernardi, R., Scaglioni, P. P., Nafa, K., Rush, L. J., et al. (2004a). Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J. Natl. Cancer Inst. 96, 269-279.
39. Gurrieri, C., Nafa, K., Merghoub, T., Bernardi, R., Capodieci, P., Biondi, A., et al. (2004b). Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood 103, 2358-2362.
40. Hanahan, D., and Weinberg, R. R. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
41. Hanif, I. M., Shazib, M. A., Ahmad, K. A., and Pervaiz, S. (2010). Casein Kinase II: an attractive target for anti-cancer drug design. Int. J. Biochem. Cell Biol. 42, 1602-1605.
42. Hayakawa, F., Abe, A., Kitabayashi, I., Pandolfi, P. P., and Naoe, T. (2008). Acetylation of PML is involved in histone deacetylase inhibitor-mediated apoptosis. J. Biol. Chem. 283, 24420-24425.
43. Hayakawa, F., and Privalsky, M. M. (2004). Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell 5, 389-401.
44. House, C. M., Moller, A., and Bowtell, D. D. (2009). Siah proteins: novel drug targets in the Ras and hypoxia pathways. Cancer Res. 69, 8835-8838.
45. Ito, K., Bernardi, R., Morotti, A., Matsuoka, S., Saglio, G., Ikeda, Y., et al. (2008). PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453, 1072-1078.
46. Ito, K., Carracedo, A., Weiss, D., Arai, F., Ala, U., Avigan, D. E., et al. (2012). A PML-PPAR-delta pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat. Med. 18, 1350-1358.
47. Jeanne, M., Lallemand-Breitenbach, V., Ferhi, O., Koken, M., Le Bras, M., Duffort, S., et al. (2010). PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 18, 88-98.
48. Jensen, K., Shiels, C., and Freemont, P. P. (2001). PML protein isoforms and the RBCC/TRIM motif. Oncogene 20, 7223-7233.
49. Kakizuka, A., Miller, W. H. Jr., Umesono, K., Warrell, R. P. Jr., Frankel, S. R., Murty, V. V., et al. (1991). Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66, 663-674.
50. Kamitani, T., Nguyen, H. P., Kito, K., Fukuda-Kamitani, T., and Yeh, E. E. (1998a). Covalent modification of PML by the sentrin family of ubiquitin-like proteins. J. Biol. Chem. 273, 3117-3120.
51. Kamitani, T., Kito, K., Nguyen, H. P., Wada, H., Fukuda-Kamitani, T., and Yeh, E. E. (1998b). Identification of three major sentrinization sites in PML. J. Biol. Chem. 273, 26675-26682.
52. Koken, M. H., Linares-Cruz, G., Quignon, F., Viron, A., Chelbi-Alix, M. K., Sobczak-Thepot, J., et al. (1995). The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene 10, 1315-1324.
53. Lallemand-Breitenbach, V., Jeanne, M., Benhenda, S., Nasr, R., Lei, M., Peres, L., et al. (2008). Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat. Cell Biol. 10, 547-555.
54. Lallemand-Breitenbach, V., Zhu, J., Puvion, F., Koken, M., Honore, N., Doubeikovsky, A., et al. (2001). Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J. Exp. Med. 193, 1361-1371.
55. Landesman-Bollag, E., Romieu-Mourez, R., Song, D. H., Sonenshein, G. E., Cardiff, R. D., and Seldin, D. D. (2001). Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 20, 3247-3257.
56. Lee, Y. R., Yuan, W. C., Ho, H. C., Chen, C. H., Shih, H. M., and Chen, R. R. (2010). The Cullin 3 substrate adaptor KLHL20 mediates DAPK ubiquitination to control interferon responses. EMBO J. 29, 1748-1761.
57. Lim, J. H., Liu, Y., Reineke, E., and Kao, H. H. (2011). Mitogen-activated protein kinase extracellular signal-regulated kinase 2 phosphorylates and promotes Pin1 protein-dependent promyelocytic leukemia protein turnover. J. Biol. Chem. 286, 44403-44411.
58. Lin, H. K., Bergmann, S., and Pandolfi, P. P. (2004). Cytoplasmic PML function in TGF-beta signalling. Nature 431, 205-211.
59. Lipkowitz, S., and Weissman, A. A. (2011). RINGs of good and evil. RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat. Rev. Cancer 11, 629-643.
60. Liu, B., Mink, S., Wong, K. A., Stein, N., Getman, C., Dempsey, P. W., et al. (2004). PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat. Immunol. 5, 891-898.
61. Liu, B., Tahk, S., Yee, K. M., Fan, G., and Shuai, K. (2010). The ligase PIAS1 restricts natural regulatory T cell differentiation by epigenetic repression. Science 330, 521-525.
62. Louria-Hayon, I., Alsheich-Bartok, O., Levav-Cohen, Y., Silberman, I., Berger, M., Grossman, T., et al. (2009). E6AP promotes the degradation of the PML tumor suppressor. Cell Death Differ. 16, 1156-1166.
63. Mallette, F. A., Goumard, S., Gaumont-Leclerc, M. F., Moiseeva, O., and Ferbeyre, G. (2004). Human fibroblasts require the Rb family of tumor suppressors, but not p53, for PML-induced senescence. Oncogene 23, 91-99.
64. Maul, G. G., Guldner, H. H., and Spivack, J. J. (1993). Modification of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICP0). J. Gen. Virol. 74(Pt 12), 2679-2690.
65. O-charoenrat, P., Rusch, V., Talbot, S. G., Sarkaria, I., Viale, A., Socci, N., et al. (2004). Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung. Clin. Cancer Res. 10, 5792-5803.
66. Pandolfi, P. P., Grignani, F., Alcalay, M., Mencarelli, A., Biondi, A., LoCoco, F., et al. (1991). Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene 6, 1285-1292.
67. Pearson, M., Carbone, R., Sebastiani, C., Cioce, M., Fagioli, M., Saito, S., et al. (2000). PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406, 207-210.
68. Pinna, L. L. (2002). Protein kinase CK2: A challenge to canons. J. Cell. Sci. 115(Pt 20), 3873-3878.
69. Rabellino, A., Carter, B., Konstantinidou, G., Wu, S. Y., Rimessi, A., Byers, L. A., et al. (2012). The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA. Cancer Res. 72, 2275-2284.
70. Regad, T., and Chelbi-Alix, M. K. (2001). Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene 20, 7274-7286.
71. Rego, E. M., Wang, Z. G., Peruzzi, D., He, L. Z., Cordon-Cardo, C., and Pandolfi, P. P. (2001). Role of promyelocytic leukemia (PML) protein in tumor suppression. J. Exp. Med. 193, 521-529.
72. Reineke, E. L., Lam, M., Liu, Q., Liu, Y., Stanya, K. J., Chang, K. S., et al. (2008). Degradation of the tumor suppressor PML by Pin1 contributes to the cancer phenotype of breast cancer MDA-MB-231 cells. Mol. Cell. Biol. 28, 997-1006.
73. Reineke, E. L., Liu, Y., and Kao, H. H. (2010). Promyelocytic leukemia protein controls cell migration in response to hydrogen peroxide and insulin-like growth factor-1. J. Biol. Chem. 285, 9485-9492.
74. Roskoski, R. Jr. (2012). ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacol. Res. 66, 105-143.
75. Roussel, M. J., and Lanotte, M. (2001). Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: Nomenclature of cells and repertory of their known genetic alterations and phenotypes. Oncogene 20, 7287-7291.
76. Rytinki, M. M., Kaikkonen, S., Pehkonen, P., Jaaskelainen, T., and Palvimo, J. J. (2009). PIAS proteins: Pleiotropic interactors associated with SUMO. Cell. Mol. Life Sci. 66, 3029-3041.
77. Sarno, S., Papinutto, E., Franchin, C., Bain, J., Elliott, M., Meggio, F., et al. (2011). ATP site-directed inhibitors of protein kinase CK2: An update. Curr. Top. Med. Chem. 11, 1340-1351.
78. Scaglioni, P. P., and Pandolfi, P. P. (2007). The theory of APL revisited. Curr. Top. Microbiol. Immunol. 313, 85-100.
79. Scaglioni, P. P., Rabellino, A., Yung, T. M., Bernardi, R., Choi, S., Konstantinidou, G., et al. (2012). Translation-dependent mechanisms lead to PML upregulation and mediate oncogenic K-RAS-induced cellular senescence. EMBO Mol. Med. 4, 594-602.
80. Scaglioni, P. P., Yung, T. M., Cai, L. F., Erdjument-Bromage, H., Kaufman, A. J., Singh, B., et al. (2006). A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 126, 269-283.
81. Schmidt, D., and Muller, S. (2002). Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc. Natl. Acad. Sci. U.S.A. 99, 2872-2877.
82. Seeler, J. S., and Dejean, A. (1999). The PML nuclear bodies: Actors or extras? Curr. Opin. Genet. Dev. 9, 362-367.
83. Seldin, D. C., and Leder, P. (1995). Casein kinase II alpha transgene-induced murine lymphoma: Relation to theileriosis in cattle. Science 267, 894-897.
84. Semenza, G. G. (2010). Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29, 625-634.
85. Shen, T. H., Lin, H. K., Scaglioni, P. P., Yung, T. M., and Pandolfi, P. P. (2006). The mechanisms of PML-nuclear body formation. Mol. Cell 24, 331-339.
86. Shuai, K., and Liu, B. (2005). Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat. Rev. Immunol. 5, 593-605.
87. Siddiqui-Jain, A., Drygin, D., Streiner, N., Chua, P., Pierre, F., O'Brien, S. E., et al. (2010). CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 70, 10288-10298.
88. Stehmeier, P., and Muller, S. (2009). Phospho-regulated SUMO interaction modules connect the SUMO system to CK2 signaling. Mol. Cell 33, 400-409.
89. Sun, H., Leverson, J. D., and Hunter, T. (2007). Conserved function of RNF4 family proteins in eukaryotes: Targeting a ubiquitin ligase to SUMOylated proteins. EMBO J. 26, 4102-4112.
90. Talis, A. L., Huibregtse, J. M., and Howley, P. P. (1998). The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J. Biol. Chem. 273, 6439-6445.
91. Tatham, M. H., Geoffroy, M. C., Shen, L., Plechanovova, A., Hattersley, N., Jaffray, E. G., et al. (2008). RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol. 10, 538-546.
92. Trotman, L. C., Alimonti, A., Scaglioni, P. P., Koutcher, J. A., Cordon-Cardo, C., and Pandolfi, P. P. (2006). Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441, 523-527.
93. Turelli, P., Doucas, V., Craig, E., Mangeat, B., Klages, N., Evans, R., et al. (2001). Cytoplasmic recruitment of INI1 and PML on incoming HIV preintegration complexes: Interference with early steps of viral replication. Mol. Cell 7, 1245-1254.
94. Wang, Z. G., Delva, L., Gaboli, M., Rivi, R., Giorgio, M., Cordon-Cardo, C., et al. (1998a). Role of PML in cell growth and the retinoic acid pathway. Science 279, 1547-1551.
95. Wang, Z. G., Ruggero, D., Ronchetti, S., Zhong, S., Gaboli, M., Rivi, R., et al. (1998b). PML is essential for multiple apoptotic pathways. Nat. Genet. 20, 266-272.
96. Wang, Z. Y., and Chen, Z. (2008). Acute promyelocytic leukemia: From highly fatal to highly curable. Blood 111, 2505-2515.
97. Wolyniec, K., Shortt, J., de Stanchina, E., Levav-Cohen, Y., Alsheich-Bartok, O., Louria-Hayon, I., et al. (2012). E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis. Blood 120, 822-832.
98. Wu, S. Y., and Chiang, C. C. (2009). Crosstalk between sumoylation and acetylation regulates p53-dependent chromatin transcription and DNA binding. EMBO J. 28, 1246-1259.
99. Wulf, G., Finn, G., Suizu, F., and Lu, K. K. (2005). Phosphorylation-specific prolyl isomerization: Is there an underlying theme? Nat. Cell. Biol. 7, 435-441.
100. Yang, S., Jeong, J. H., Brown, A. L., Lee, C. H., Pandolfi, P. P., Chung, J. H., et al. (2006). Promyelocytic leukemia activates Chk2 by mediating Chk2 autophosphorylation. J. Biol. Chem. 281, 26645-26654.
101. Yuan, W. C., Lee, Y. R., Huang, S. F., Lin, Y. M., Chen, T. Y., Chung, H. C., et al. (2011). A Cullin3-KLHL20 Ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression. Cancer Cell 20, 214-228.
102. Zhang, X. W., Yan, X. J., Zhou, Z. R., Yang, F. F., Wu, Z. Y., Sun, H. B., et al. (2010). Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328, 240-243.
103. Zhong, S., Salomoni, P., and Pandolfi, P. P. (2000a). The transcriptional role of PML and the nuclear body. Nat. Cell Biol. 2, E85-E90.
104. Zhong, S., Muller, S., Ronchetti, S., Freemont, P. S., Dejean, A., and Pandolfi, P. P. (2000b). Role of SUMO-1-modified PML in nuclear body formation. Blood 95, 2748-2752.
105. Zhu, J., Zhou, J., Peres, L., Riaucoux, F., Honore, N., Kogan, S., et al. (2005). A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell 7, 143-153.